学术周报 · IF≥10

肾内科领域文献阅读汇编

2026年第42周 (2026-10-17) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
13
临床研究
2
基础研究
11
IF≥20
2
IF 10-20
11
子领域
5
期刊种类
12
数据日期
2026-10-17

★本周 Top 10 高影响力文献

#论文期刊IF
1Capillary-selective vasodilation through myosin inhibition halts ischaemic cascades.NatureIF 56.1
2A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL a...BloodIF 23.9
3Calprotectin Accelerates Pathogenic Calciprotein Particle Maturation to Promote Vascular Calcificati...Circulation researchIF 18.0
4Quinolinic acid contributes to maladaptive kidney injury and acute kidney injury-to-chronic kidney d...Science translational medicineIF 15.6
5Advanced Glycation End Products: From Pathogenesis to Treatment.MedCommIF 14.1
6Preparation of reactive oxygen species-responsive chitosan oligosaccharide nanoparticles and their t...Carbohydrate polymersIF 13.2
7Epigenetically silencing gluconeogenic enzyme PCK1 by EZH2 promotes renal tubulointerstitial fibrosi...Molecular biomedicineIF 13.0
8Heart-to-kidney signal by extracellular vesicles promotes kidney injury in cardiorenal syndrome.Cardiovascular researchIF 12.5
9Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improv...Cardiovascular researchIF 12.5
10Research on the expression of miR-192-5p in extracellular vesicles of diabetic nephropathy based on ...Biosensors & bioelectronicsIF 11.8

Ŧ期刊分布统计

期刊篇数IF
Cardiovascular research2IF 12.5
European journal of heart failure1IF 10.3
Carbohydrate polymers1IF 13.2
Blood1IF 23.9
Advanced healthcare materials1IF 11.0
Nature1IF 56.1
Science translational medicine1IF 15.6
Molecular biomedicine1IF 13.0
Clinical reviews in allergy & immunology1IF 11.5
MedComm1IF 14.1

1慢性肾脏病 CKD (6篇)

临床研究 (1篇)

European journal of heart failure IF 10.3 2026-10-17 PMID: 42888496
Concentrations of N-terminal pro-B type natriuretic peptide (NT-proBNP) is central to acute heart failure (AHF) diagnosis in dyspneic emergency departments (ED) patients, but optimal thresholds remain uncertain. This study aimed to evaluate the diagnostic accuracy of various NT-proBNP thresholds for AHF, across the general population and these key subgroups. A systematic review and meta-analysis were conducted, including studies published up to August 28, 2025, that reported the diagnostic performance of NT-proBNP thresholds for AHF in dyspneic ED patients. The analysis included 31 studies comprising 26,948 patients. To exclude AHF, a fixed threshold of ≤300 ng/L yielded an area under the receiver operator characteristic curve (AUC) of 0.73 (0.69-0.77), with high sensitivity of 97.9% (96.9-98.5) and lower specificity of 46.2% (36.4-56.2); the negative predictive value of this threshold was 97.0% (96.5-97.4). Age-dependent thresholds (≥450 ng/L for patients aged <50 years, ≥900 ng/L for those aged 50-75 years, and ≥1,800 ng/L for those aged ≥75 years), evaluated in 14,410 patients, achieved an AUC of 0.84 (0.83-0.85) with a more favorable balance between sensitivity of 85.9% (85.0-86.7) and specificity of 82.0% (81.2-82.9). In patients with CKD (N=2,271), all fixed thresholds yielded AUC <0.80; age-dependent thresholds showed an AUC of 0.77 (0.75-0.78) with specificity of 62.6% (59.4-65.7). In patients with obesity (body mass index ≥30), only age-dependent thresholds were assessed, in 3,562 patients; AUC was 0.82 (0.81-0.84) and sensitivity was 81.2% (79.2-83.1), broadly comparable to the overall population. A threshold ≤300 ng/L provides excellent rule-out performance for AHF, while age-dependent NT-proBNP thresholds offer superior diagnostic performance for ruling in AHF in the ED compared to fixed thresholds, and demonstrate consistent accuracy across subgroups. However, evidence in patients with CKD and obesity remains limited, both in terms of sample size and the range of thresholds evaluated.
中文摘要:N末端B型利钠肽原(NT-proBNP)浓度是急诊科呼吸困难患者急性心力衰竭(AHF)诊断的核心指标,但最佳阈值仍不确定。研究旨在评估不同NT-proBNP阈值对AHF的诊断准确性,覆盖总体人群及若干关键亚组。系统评价与Meta分析纳入截至2025年8月28日发表、报告急诊呼吸困难患者NT-proBNP阈值诊断性能的研究,共31项研究、26,948例患者。用于排除AHF时,固定阈值≤300 ng/L的受试者工作特征曲线下面积(AUC)为0.73(0.69-0.77),敏感性高,为97.9%(96.9-98.5),特异性较低,为46.2%(36.4-56.2);该阈值的阴性预测值为97.0%(96.5-97.4)。年龄依赖阈值(<50岁≥450 ng/L,50-75岁≥900 ng/L,≥75岁≥1,800 ng/L)在14,410例患者中评估,AUC为0.84(0.83-0.85),敏感性85.9%(85.0-86.7)与特异性82.0%(81.2-82.9)之间平衡更好。慢性肾脏病(CKD)患者(N=2,271)中,所有固定阈值的AUC均<0.80;年龄依赖阈值AUC为0.77(0.75-0.78),特异性62.6%(59.4-65.7)。肥胖(体质指数≥30)患者仅评估了年龄依赖阈值,共3,562例,AUC为0.82(0.81-0.84),敏感性81.2%(79.2-83.1),与总体人群大致相当。阈值≤300 ng/L对AHF具有很好的排除效能,年龄依赖NT-proBNP阈值在急诊中用于确诊AHF的诊断性能优于固定阈值,且在各亚组中准确性一致。但CKD与肥胖患者的证据在样本量和所评估阈值范围两方面仍有限。

基础研究 (5篇)

Carbohydrate polymers IF 13.2 2026-10-15 PMID: 42692609
Diabetic nephropathy (DN) is a severe complication of diabetes, strongly associated with hyperglycemia-induced oxidative stress. In this study, we developed ROS-responsive nanoparticles (PC-E-CAN NPs) based on chitosan oligosaccharides (CS) for dual-drug co-delivery. Chitosan oligosaccharides were functionalized with 3-carboxyphenylboronic acid (PBA), loaded with epigallocatechin gallate (EGCG) and canagliflozin (CAN), and cross-linked via a thioketal (TK) to form ROS-sensitive nanoparticles. The resulting PC-E-CAN NPs exhibited a uniform particle size of 110 ± 1.8 nm, with drug loading efficiencies of 16.6 ± 0.7% for EGCG and 10.1 ± 0.6% for CAN. PC-E-CAN NPs were efficiently internalized by renal tubular epithelial cells (HK-2 cells), significantly reducing intracellular ROS accumulation and suppressing oxidative stress-induced apoptosis. Under high ROS conditions, both drugs were rapidly released in a responsive manner, with ≥70% cumulative release at 48 h. In vivo experiments revealed that PC-E-CAN NPs accumulated in the kidneys, suggesting potential tubular uptake, significantly reducing blood glucose levels in DN mice, improving renal function (urine protein, creatinine, urea nitrogen), and alleviating renal pathological damage and oxidative stress. This strategy integrates three critical features: ROS-responsive drug release, renal accumulation via appropriate particle size, and combined dual-drug therapy, providing a promising precise treatment for DN.
中文摘要:糖尿病肾病(DN)是糖尿病的严重并发症,与高血糖诱导的氧化应激密切相关。本研究基于壳寡糖(CS)构建了活性氧(ROS)响应性纳米颗粒(PC-E-CAN NPs),用于双药共递送。壳寡糖经3-羧基苯硼酸(PBA)功能化,负载表没食子儿茶素没食子酸酯(EGCG)和卡格列净(CAN),并通过硫缩酮(TK)交联形成ROS敏感纳米颗粒。所得PC-E-CAN NPs粒径均一,为110±1.8 nm,EGCG和CAN的载药效率分别为16.6±0.7%和10.1±0.6%。PC-E-CAN NPs可被肾小管上皮细胞(HK-2细胞)高效内化,显著降低细胞内ROS蓄积并抑制氧化应激诱导的凋亡。在高ROS条件下,两种药物以响应方式快速释放,48 h累积释放率≥70%。体内实验显示PC-E-CAN NPs在肾脏蓄积,提示可能经肾小管摄取,显著降低DN小鼠血糖水平,改善肾功能(尿蛋白、肌酐、尿素氮),并减轻肾脏病理损伤和氧化应激。该策略整合了ROS响应性药物释放、适宜粒径介导的肾脏蓄积和双药联合治疗三个关键特征,为DN的精准治疗提供了有前景的方案。
Science translational medicine IF 15.6 2026-10-14 PMID: 42873891
The transition from acute kidney injury (AKI) to chronic kidney disease (CKD) remains a major clinical problem with unclear underlying mechanisms. Emerging evidence suggests that alterations in tryptophan metabolism, particularly in the production of downstream metabolites such as quinolinic acid (QA), play a role in renal pathophysiology. QA, an intermediate in de novo nicotinamide adenine dinucleotide biosynthesis, is metabolized by quinolinate phosphoribosyltransferase (QPRT). We investigated whether QA contributes to kidney injury using models of folic acid-induced AKI-to-CKD transition and cisplatin-induced AKI, genetic and exogenous approaches to alter QA, and clinical observations. Untargeted kidney metabolomics identified QA as one of the most elevated metabolites after folic acid injury. After folic acid injury, Qprt haploinsufficiency exacerbated kidney injury and fibrosis-related gene expression; aged Qprt-haploinsufficient mice exhibited increased fibrosis-associated gene expression without overt renal dysfunction. Exogenous QA administration increased serum creatinine in uninjured mice and worsened renal dysfunction and fibrosis-related gene expression in the folic acid AKI-to-CKD model. Conversely, mice deficient in either 3-hydroxyanthranilate 3,4-dioxygenase (HAAO) or kynurenine 3-monooxygenase (KMO), which reduce flux toward QA, showed improved renal outcomes after folic acid injury and cisplatin-induced AKI. Multimodal spatial metabolomics analysis of kidney biopsies from patients with AKI revealed QA accumulation in regions of inflammatory infiltration. Last, children with CKD exhibited higher urinary QA compared with healthy individuals. These findings underscore QA as a potential mediator of kidney injury and a therapeutic target for preventing the progression from AKI to CKD.
中文摘要:急性肾损伤(AKI)向慢性肾脏病(CKD)的转化仍是重大临床问题,机制尚不清楚。越来越多证据提示色氨酸代谢改变,尤其是下游代谢物喹啉酸(QA)生成的变化,参与肾脏病理生理。QA 是烟酰胺腺嘌呤二核苷酸从头合成中的中间产物,由喹啉酸磷酸核糖转移酶(QPRT)代谢。我们利用叶酸诱导的 AKI 向 CKD 转化模型和顺铂诱导的 AKI 模型,结合改变 QA 的遗传与外源性方法以及临床观察,研究 QA 是否参与肾损伤。肾脏非靶向代谢组学发现,叶酸损伤后 QA 是升高最明显的代谢物之一。叶酸损伤后,Qprt 单倍体不足加重肾损伤及纤维化相关基因表达;老龄 Qprt 单倍体不足小鼠纤维化相关基因表达增加,但无明显肾功能异常。外源性 QA 使未损伤小鼠血肌酐升高,并在叶酸 AKI 向 CKD 模型中加重肾功能异常和纤维化相关基因表达。相反,缺乏 3-羟基邻氨基苯甲酸 3,4-双加氧酶(HAAO)或犬尿氨酸 3-单加氧酶(KMO)的小鼠,其通向 QA 的通量降低,在叶酸损伤和顺铂诱导的 AKI 后肾脏结局改善。对 AKI 患者肾活检的多模态空间代谢组学分析显示,QA 在炎症浸润区域蓄积。CKD 患儿尿 QA 也高于健康个体。这些发现提示 QA 可能是肾损伤的介导因素,也是阻止 AKI 向 CKD 进展的治疗靶点。
MedComm IF 14.1 2026-10 PMID: 42871839
Advanced glycation end products (AGEs) are chemically heterogeneous modifications generated through nonenzymatic glycation, glycoxidation, and carbonyl stress. Their accumulation increases during aging and is accelerated by hyperglycemia, oxidative stress, inflammation, exogenous exposure, and impaired renal clearance. Although AGE biology has often been framed around the AGE-RAGE-oxidative stress axis, current evidence supports a broader systems-level model in which AGE burden reflects the balance among formation, detoxification, tissue retention, and clearance. This review summarizes AGE chemistry, endogenous and exogenous sources, detoxification pathways, receptor systems, and mechanisms of AGE-mediated tissue injury. We distinguish two complementary pathogenic routes: receptor-independent structural damage, including protein dysfunction, proteostatic stress, extracellular matrix crosslinking, and altered tissue mechanics; and receptor-dependent signaling, mainly through RAGE-mediated redox-inflammatory amplification. We then examine the clinical relevance of AGEs in diabetes, cardiovascular disease, chronic kidney disease, neurovascular and retinal dysfunction, fibrosis, and aging-related tissue decline. Particular attention is given to compartment-specific biomarker interpretation, because circulating free adducts, protein-bound AGEs, tissue autofluorescence, dietary AGE estimates, and dicarbonyl stress markers are not interchangeable. Finally, we evaluate therapeutic strategies and propose a framework that matches each intervention to the relevant mechanism and can be tested clinically. In doing so, the review clarifies major conceptual and methodological uncertainties in AGE research and provides a foundation for more rigorous biomarker interpretation, study design, and clinical translation.
中文摘要:晚期糖基化终末产物(AGEs)是一类通过非酶糖化、糖氧化和羰基应激生成的化学异质性修饰。其蓄积随衰老增加,并受到高血糖、氧化应激、炎症、外源性暴露和肾脏清除受损的加速。AGE生物学常围绕AGE-RAGE-氧化应激轴展开,现有证据则支持更广泛的系统层面模型,即AGE负荷反映形成、解毒、组织滞留和清除之间的平衡。该综述总结AGE化学、内源性和外源性来源、解毒途径、受体系统以及AGE介导组织损伤的机制。文中区分两条互补的致病路径:不依赖受体的结构损伤,包括蛋白质功能障碍、蛋白质稳态应激、细胞外基质交联和组织力学改变;依赖受体的信号传导,主要通过RAGE介导的氧化还原-炎症放大。随后讨论AGE在糖尿病、心血管疾病、慢性肾脏病、神经血管和视网膜功能障碍、纤维化及衰老相关组织衰退中的临床相关性。重点放在区室特异性生物标志物解读,因为循环游离加合物、蛋白结合型AGEs、组织自发荧光、膳食AGE估算和双羰基应激标志物并不可互换。最后评估治疗策略,提出将每项干预与相关机制匹配并可在临床中检验的框架。由此,综述厘清AGE研究中的主要概念和方法学不确定性,为更严谨的生物标志物解读、研究设计和临床转化提供基础。
Circulation research IF 18.0 2026-10-12 PMID: 42861523
Vascular calcification is a hallmark of chronic kidney disease (CKD)-mineral and bone disorder and a major determinant of cardiovascular mortality. Secondary calciprotein particles (CPP2) are key mediators of vascular calcification; however, the mechanisms regulating their maturation and pathogenic properties remain incompletely understood. CPT (Calprotectin, S100A8/A9), a myeloid-derived inflammatory mediator, is elevated in CKD and predicts cardiovascular events and mortality, particularly under high-phosphate conditions, but the underlying mechanisms remain unclear. We investigated the role of CPT in vascular calcification using CKD-mineral and bone disorder mice with myeloid-specific CPT deletion. Aortic calcification was assessed by ex vivo imaging, histology, and calcium quantification. Serum calciprotein particle (CPP) fractions were determined by flow cytometry. Mechanistic studies were performed in vascular smooth muscle cells exposed to CPP2 in the presence or absence of macrophage-derived CPT. Calcification propensity was evaluated using the T50 assay, and CPP2 elemental composition was analyzed by high-angle annular dark-field scanning transmission electron microscopy-energy-dispersive X-ray spectroscopy. Myeloid-specific CPT deletion significantly attenuated aortic calcification and osteogenic gene expression in CKD-mineral and bone disorder mice without altering renal function or systemic mineral parameters. These changes were accompanied by an increased circulating immature CPP fraction. Macrophage-derived CPT markedly enhanced CPP2-induced vascular smooth muscle cell calcification by accelerating CPP maturation, reflected by a shortened T50, and by altering CPP2 composition to be enriched in calcium and phosphate. Although no direct interaction between CPT and CPPs was detected, CPT modified the physicochemical milieu, including ionized calcium and pH. Consistently, CPP2 from CPT-deficient serum exhibited substantially reduced calcification potency, indicating that CPT shapes CPP pathogenicity by modulating particle quality rather than quantity. Importantly, CPT-mediated CPP maturation occurred in a cell-free milieu, indicating a TLR4-independent mechanism distinct from its known receptor-mediated actions. CPT is a previously unrecognized regulator of pathogenic CPP maturation and composition, thereby promoting vascular calcification in CKD-mineral and bone disorder. Targeting CPT may represent a novel therapeutic strategy to attenuate vascular calcification in CKD.
中文摘要:血管钙化是慢性肾脏病(CKD)矿物质与骨代谢异常的标志,也是心血管死亡的主要决定因素。继发性钙蛋白颗粒(CPP2)是血管钙化的关键介质,但其成熟及致病特性的调控机制仍未完全阐明。CPT(钙卫蛋白,S100A8/A9)是一种髓系来源的炎症介质,在CKD中升高,并可预测心血管事件和死亡,尤其在高磷条件下,但其潜在机制尚不清楚。我们利用髓系特异性CPT敲除的CKD矿物质与骨代谢异常小鼠,研究CPT在血管钙化中的作用。通过离体成像、组织学和钙定量评估主动脉钙化。采用流式细胞术测定血清钙蛋白颗粒(CPP)组分。机制研究在暴露于CPP2并存在或无巨噬细胞来源CPT的血管平滑肌细胞中进行。使用T50试验评估钙化倾向,并通过高角环形暗场扫描透射电子显微镜-能量色散X射线光谱分析CPP2的元素组成。髓系特异性CPT缺失显著减轻CKD矿物质与骨代谢异常小鼠的主动脉钙化和成骨基因表达,而未改变肾功能或全身矿物质参数。这些变化伴随循环中未成熟CPP组分增加。巨噬细胞来源CPT通过加速CPP成熟(表现为T50缩短)和改变CPP2组成使其富含钙和磷酸盐,显著增强CPP2诱导的血管平滑肌细胞钙化。尽管未检测到CPT与CPP之间的直接相互作用,CPT改变了物理化学环境,包括离子钙和pH。来自CPT缺陷血清的CPP2钙化效力显著降低,表明CPT通过调节颗粒质量而非数量来塑造CPP的致病性。CPT介导的CPP成熟可在无细胞环境中发生,提示其机制不依赖TLR4,不同于其已知的受体介导作用。CPT是致病性CPP成熟和组成的先前未被认识的调节因子,从而促进CKD矿物质与骨代谢异常中的血管钙化。靶向CPT可能是减轻CKD血管钙化的新治疗策略。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42578286
Chronic kidney disease (CKD) is associated with uraemic cardiomyopathy characterized by early metabolic dysfunction. Elevated myocardial intracellular sodium (Naᵢ) has emerged as a driver of cardiometabolic remodelling, however, its role in CKD and therapeutic modulation remains unclear. We investigated whether dual sodium-glucose cotransporter (SGLT)1/2 inhibition with sotagliflozin (SOTA) targets Naᵢ and improves cardiac metabolism in CKD. CKD was induced in male Wistar rats by 5/6 nephrectomy and assessed after 4 weeks. Cardiac phenotype was evaluated using in vivo echocardiography and ex vivo Langendorff perfusion combined with 23Na and 31P NMR spectroscopy. CKD hearts exhibited preserved systolic but impaired diastolic function and a marked elevation in myocardial Naᵢ, identifying Naᵢ overload as an early feature of uraemic cardiomyopathy. Cardiac metabolomic profiling and flux modelling demonstrated widespread suppression of central carbon metabolism, redox imbalance despite preserved PCr/ATP. In silico electrophysiological simulations predicted Naᵢ-driven Ca2+ dysregulation consistent with in vivo diastolic dysfunction. Chronic SOTA treatment (3 weeks, in vivo) normalized myocardial Naᵢ and partially reversed metabolic remodelling. Acute SOTA exposure (20 min, Langendorff-perfusion) similarly reduced Naᵢ in CKD hearts but not in controls, indicating a direct, disease-selective myocardial effect. Naᵢ normalization was accompanied by improved redox state and restoration of mitochondrial metabolic flux, without changes in expression of canonical Na + -handling proteins. Myocardial Naᵢ overload emerges as an early and potentially modifiable feature of uraemic cardiomyopathy. Dual SGLT1/2 inhibition with SOTA directly lowers Naᵢ and improves cardiac metabolic homeostasis, supporting Naᵢ as a mechanistically relevant and potentially targetable pathway in CKD-related cardiac remodelling.
中文摘要:慢性肾脏病(CKD)与尿毒症性心肌病相关,后者以早期代谢功能障碍为特征。心肌细胞内钠(Naᵢ)升高已被视为心脏代谢重构的驱动因素,但其在CKD中的作用及治疗性调控仍不清楚。研究采用索格列净(SOTA)双重抑制钠-葡萄糖协同转运蛋白(SGLT)1/2,观察其是否靶向Naᵢ并改善CKD心脏代谢。通过5/6肾切除术在雄性Wistar大鼠中诱导CKD,并于4周后评估。采用在体超声心动图和离体Langendorff灌注结合23Na与31P核磁共振波谱评估心脏表型。CKD心脏收缩功能保留但舒张功能受损,心肌Naᵢ显著升高,提示Naᵢ超载是尿毒症性心肌病的早期特征。心脏代谢组学分析和通量建模显示中心碳代谢广泛受抑、氧化还原失衡,而PCr/ATP保持。计算机电生理模拟预测Naᵢ驱动Ca2+失调,与在体舒张功能障碍一致。长期SOTA治疗(3周,在体)使心肌Naᵢ正常化并部分逆转代谢重构。急性SOTA暴露(20分钟,Langendorff灌注)同样降低CKD心脏Naᵢ,而对照组无此变化,表明存在直接的疾病选择性心肌效应。Naᵢ正常化伴随氧化还原状态改善和线粒体代谢通量恢复,而经典Na+调控蛋白表达未见改变。心肌Naᵢ超载是尿毒症性心肌病早期且可能可调控的特征。SOTA双重抑制SGLT1/2可直接降低Naᵢ并改善心脏代谢稳态,支持Naᵢ作为CKD相关心脏重构中具有机制相关性且可能可靶向的通路。

2急性肾损伤 AKI (4篇)

临床研究 (1篇)

Blood IF 23.9 2026-10-15 PMID: 42296025
Treatment options for patients with immunoglobulin light chain (AL) amyloidosis and advanced cardiac involvement remain limited. The prospective phase 2 European Myeloma Network 22 trial included patients with previously untreated AL amyloidosis, measurable hematologic disease, and Mayo2004/European cardiac stage IIIB disease to receive daratumumab monotherapy at the standard dose and schedule for up to 2 years (28-day cycles); patients with inadequate response after 3 cycles could additionally receive weekly bortezomib and dexamethasone. The primary end point was 6-month overall survival (OS) rate. Of 40 patients enrolled, 10 (25.0%) received additional treatment with bortezomib and dexamethasone. The 6-month OS rate was 65% (95% confidence interval, 48.2-77.6), and median OS was 10.4 months. The best hematologic response rate (partial response or better) up to 6 months was 75% (very good partial response or better, 47.5%; complete response, 12.5%), with the median time to first and best hematologic response being 1 week and 2.3 months, respectively. Cardiac response rate at 6 months was 30%. Common serious adverse events were cardiac failure (25%), sudden cardiac death (10%), and acute kidney injury (7.5%). The patients' quality of life remained stable throughout the trial treatment and observation. In patients with high-risk, advanced (stage IIIB) AL amyloidosis, daratumumab monotherapy was feasible and well tolerated, achieving rapid hematologic responses and associated with prolonged survival relative to historical cohorts. Cardiac response rates at 6 months were significant, considering advanced cardiac disease. These findings support daratumumab as the backbone of anticlonal therapy in advanced cardiac AL amyloidosis. This trial was registered at www.clinicaltrials.gov as #NCT04131309.
中文摘要:免疫球蛋白轻链(AL)淀粉样变性合并晚期心脏受累患者的治疗选择仍然有限。前瞻性2期欧洲骨髓瘤网络22试验纳入既往未治疗、可测量血液学疾病且为Mayo2004/欧洲心脏分期IIIB的AL淀粉样变性患者,接受标准剂量和方案的达雷妥尤单抗单药治疗,最长2年(28天周期);3个周期后反应不足者可加用每周硼替佐米和地塞米松。主要终点为6个月总生存(OS)率。入组40例患者中,10例(25.0%)接受了硼替佐米和地塞米松额外治疗。6个月OS率为65%(95%置信区间48.2-77.6),中位OS为10.4个月。至6个月最佳血液学缓解率(部分缓解或更好)为75%(非常好的部分缓解或更好47.5%;完全缓解12.5%),首次和最佳血液学缓解的中位时间分别为1周和2.3个月。6个月心脏缓解率为30%。常见严重不良事件为心力衰竭(25%)、心脏性猝死(10%)和急性肾损伤(7.5%)。患者在试验治疗和观察期间生活质量保持稳定。在高危晚期(IIIB期)AL淀粉样变性患者中,达雷妥尤单抗单药治疗可行且耐受良好,获得快速血液学缓解,并与历史队列相比延长生存。考虑晚期心脏病,6个月心脏缓解率具有意义。这些发现支持达雷妥尤单抗作为晚期心脏AL淀粉样变性抗克隆治疗的骨架。该试验在www.clinicaltrials.gov注册为#NCT04131309。

基础研究 (3篇)

Advanced healthcare materials IF 11.0 2026-10-14 PMID: 42875953
Acute kidney injury (AKI) is a life-threatening clinical syndrome characterized by abrupt renal dysfunction, excessive oxidative stress, inflammatory activation, and profound metabolic disturbances, yet effective therapeutic strategies remain limited. Herein, we developed an ultrasmall pH-responsive nanoplatform (FeAst) through the self-assembly of Fe3+ and the natural flavonoid Astragalin (Ast) for injury-responsive renal delivery and metabolic intervention. The Fe3+-phenolic coordination network endows FeAst with excellent biocompatibility, intrinsic reactive oxygen species (ROS)-scavenging capacity, and mitochondria-targeting capability. Importantly, FeAst preferentially accumulated in injured kidneys, enabling targeted renal delivery. Moreover, the mildly acidic microenvironment associated with AKI triggered partial dissociation of the coordination network, enabling localized Ast release and sustained therapeutic activity. Across multiple experimental models of kidney injury, FeAst markedly improved renal function, alleviated tubular injury, suppressed inflammatory responses, and restored redox homeostasis. Mechanistically, FeAst preserved mitochondrial integrity, re-established glutathione-dependent antioxidant defense, suppressed ferroptosis-related processes by reducing lipid peroxidation and restoring ferroptosis defense systems, and reprogrammed TCA cycle-associated energy metabolism. Moreover, FeAst activated PPAR signaling and suppressed p38 MAPK/NF-κB-mediated inflammatory responses, thereby enhancing cellular bioenergetics and resistance to oxidative stress. Collectively, this injury-responsive nanoplatform integrates selective renal accumulation, controlled drug release, and metabolic reprogramming to provide a promising strategy for precision kidney injury therapy.
中文摘要:急性肾损伤(AKI)是一种危及生命的临床综合征,表现为肾功能突然恶化、氧化应激过度、炎症激活和显著代谢紊乱,有效治疗策略仍有限。为此,我们通过Fe3+与天然黄酮类化合物黄芪苷(Astragalin,Ast)自组装,构建了一种超小pH响应纳米平台(FeAst),用于损伤响应性肾脏递送和代谢干预。Fe3+-酚配位网络赋予FeAst良好的生物相容性、内在活性氧(ROS)清除能力和线粒体靶向能力。FeAst优先在受损肾脏中蓄积,实现靶向肾脏递送。AKI相关的弱酸性微环境触发配位网络部分解离,促使Ast在局部释放并维持治疗活性。在多种肾损伤实验模型中,FeAst显著改善肾功能、减轻肾小管损伤、抑制炎症反应并恢复氧化还原稳态。机制上,FeAst保护线粒体完整性,重建谷胱甘肽依赖性抗氧化防御,通过减少脂质过氧化和恢复铁死亡防御系统抑制铁死亡相关过程,并重编程TCA循环相关能量代谢。FeAst还激活PPAR信号并抑制p38 MAPK/NF-κB介导的炎症反应,从而增强细胞生物能量和对氧化应激的抵抗。该损伤响应纳米平台整合选择性肾脏蓄积、受控药物释放和代谢重编程,为精准肾损伤治疗提供了有前景的策略。
Nature IF 56.1 2026-10-14 PMID: 42875490
In acute myocardial infarction and acute kidney injury, capillary no-reflow denotes that capillary blood flow is still blocked despite successful arterial reperfusion. This is associated with substantially increased mortality and reinfarction risk; nevertheless, no targeted therapy exists so far1,2. Because capillary no-reflow is driven by smooth muscle myosin-mediated hypercontraction of capillary pericytes, we developed R(+)2501, a myosin-specific and capillary-selective vasodilator. In reperfused animal models of acute myocardial infarction and acute kidney injury, direct in vivo imaging showed that R(+)2501 rapidly restored capillary flow, an effect sustained even after rapid drug clearance. Ex vivo experiments confirmed reversal of pericyte constriction directly. Restoration of capillary blood flow, together with clearance of trapped neutrophils, linked resolution of capillary no-reflow to attenuation of an early driver of reperfusion injury. R(+)2501 enhanced capillary perfusion while preserving coronary autoregulation and systemic haemodynamics, and markedly improved survival during acute reperfusion. We further found that acute myocardial infarction induced renal capillary no-reflow, which was reversed by R(+)2501, suggesting that capillary no-reflow contributes to the pathophysiology of cardiorenal syndrome type I. These findings establish pericyte-targeted smooth muscle myosin inhibition as a therapeutic strategy to restore microvascular perfusion and halt the ischaemic cascade across organs, while defining a specific physiological role for capillaries and pericytes in circulatory regulation.
中文摘要:在急性心肌梗死和急性肾损伤中,毛细血管无复流指动脉再灌注成功后毛细血管血流仍受阻,这与死亡率和再梗死风险显著升高相关,但目前尚无靶向治疗。毛细血管无复流由平滑肌肌球蛋白介导的毛细血管周细胞过度收缩驱动,因此我们开发了R(+)2501,一种肌球蛋白特异性且毛细血管选择性的血管扩张剂。在再灌注的急性心肌梗死和急性肾损伤动物模型中,直接活体成像显示R(+)2501迅速恢复毛细血管血流,且该效应在药物快速清除后仍持续。离体实验直接证实了周细胞收缩的逆转。毛细血管血流恢复并清除滞留的中性粒细胞,将毛细血管无复流的缓解与再灌注损伤早期驱动因素的减轻联系起来。R(+)2501增强毛细血管灌注,同时保留冠状动脉自动调节和全身血流动力学,并显著提高急性再灌注期间的生存率。我们进一步发现急性心肌梗死可诱导肾毛细血管无复流,R(+)2501可逆转这一现象,提示毛细血管无复流参与I型心肾综合征的病理生理。这些发现确立了靶向周细胞的平滑肌肌球蛋白抑制作为一种恢复微血管灌注并阻断跨器官缺血级联的治疗策略,同时明确了毛细血管和周细胞在循环调节中的特定生理作用。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42855910
Cardiorenal syndrome type-1 (CRS1), defined as acute kidney injury occurring in the setting of acute cardiac illness, is associated with substantial morbidity and mortality. Our objective was to determine whether extracellular vesicles (EVs) derived from the injured heart localize to the kidneys and contribute to renal injury in CRS1, and to elucidate mechanisms by which cardiac-derived EVs mediate kidney damage. Using cardiomyocyte-specific EV reporter mice, we characterized the release of cardiac-derived EVs and their biodistribution to the kidneys. Acute myocardial infarction increased circulating levels of these EVs and enhanced their uptake by proximal tubular epithelial cells. To directly assess their impact on the kidney, EVs derived from cardiomyocytes cultured under normoxic (N-EV) or hypoxic (H-EV) conditions were injected into the renal arteries of wild-type mice. H-EV, but not N-EV, induced proximal tubular epithelial cell injury and worsening of kidney function. To identify EV biomarkers, we performed proteomic profiling of cargo from N-EV and H-EV, and validated the muscle-specific protein TRIM72 as a biomarker of EVs originating from injured cardiomyocytes. In a porcine CRS1 model, plasma levels of TRIM72 positive-EVs were increased, and we demonstrate their delivery to the kidney. Similarly, in CRS1 patients, higher plasma levels of TRIM72-positive EVs correlated with the development of acute kidney injury. Mechanistically, uptake of H-EVs by proximal tubular epithelial cells induced transcription of lipogenic genes and caused lipid accumulation, whereas lipogenesis blockade protected these cells from H-EV-induced injury. We subsequently found that reduced expression of the transcription factor FOXO3 drove H-EV-induced transcriptomic reprogramming. H-EV cargo was enriched with specific Foxo3-targeting miRNAs, whose delivery promoted proximal tubular epithelial cell cytotoxicity, oxidative stress, and suppressed FOXO3 levels. Overall, this work demonstrates that a Foxo3-targeting miRNA heart-to-kidney signal mediated by injured cardiac-derived EVs contributes to kidney injury in CRS1.
中文摘要:1型心肾综合征(CRS1)指急性心脏疾病背景下发生的急性肾损伤,伴随较高的发病率和死亡率。研究旨在确定损伤心脏来源的细胞外囊泡(EVs)是否定位于肾脏并参与CRS1肾损伤,并阐明心脏来源EVs介导肾损伤的机制。利用心肌细胞特异性EV报告小鼠,刻画了心脏来源EVs的释放及其向肾脏的生物分布。急性心肌梗死提高这些EVs的循环水平并增强近端小管上皮细胞对其摄取。为直接评估其对肾脏的影响,将常氧(N-EV)或低氧(H-EV)条件下培养的心肌细胞来源EVs注入野生型小鼠肾动脉。H-EV而非N-EV诱导近端小管上皮细胞损伤和肾功能恶化。为识别EV生物标志物,对N-EV和H-EV货物进行蛋白质组学分析,并验证肌肉特异性蛋白TRIM72作为损伤心肌细胞来源EVs的生物标志物。在猪CRS1模型中,血浆TRIM72阳性EVs水平升高,并证明其递送至肾脏。在CRS1患者中,较高的血浆TRIM72阳性EVs水平与急性肾损伤发生相关。机制上,近端小管上皮细胞摄取H-EVs诱导脂肪生成基因转录并造成脂质蓄积,而阻断脂肪生成可保护这些细胞免受H-EV诱导的损伤。随后发现转录因子FOXO3表达降低驱动H-EV诱导的转录组重编程。H-EV货物富含特异性靶向Foxo3的miRNA,其递送促进近端小管上皮细胞细胞毒性、氧化应激并抑制FOXO3水平。该工作表明损伤心脏来源EVs介导的靶向Foxo3的miRNA心-肾信号参与CRS1肾损伤。

3基础/转化研究 (1篇)

基础研究 (1篇)

Molecular biomedicine IF 13.0 2026-10-14 PMID: 42873444
Chronic kidney disease (CKD) is a leading cause of global morbidity. The kidney is a major gluconeogenic organ, and impaired renal gluconeogenesis contributes to CKD, yet the regulatory mechanisms remain poorly understood. Here we show that enhancer of zeste homolog 2 (EZH2), a histone H3K27 trimethyltransferase, epigenetically suppresses renal gluconeogenesis and drives tubulointerstitial fibrosis. Through integrative multi-omics profiling (RNA-seq, CUT&Tag, and single-nucleus RNA-seq), we show that EZH2 directly binds to and deposits H3K27 trimethylation at promoters of gluconeogenic genes in proximal tubular cells, with the most prominent repression observed at phosphoenolpyruvate carboxykinase (Pck1) gene. In fibrotic kidneys, Ezh2 is markedly upregulated in proximal tubules and inversely correlates with Pck1 expression across injury and maladaptive repair states. Genetic ablation or pharmacological inhibition of EZH2 restores PCK1 expression, enhances lactate-to-glucose conversion, and attenuates extracellular matrix deposition and fibrotic marker expression in both cultured tubular cells and mouse models of kidney fibrosis. Stable isotope 13C-lactate tracing shows that tubular Ezh2 deletion increases the labelling fractions of gluconeogenic intermediates while reducing the labelling fraction of acetyl-CoA, indicating preferential partitioning of lactate-derived carbon towards gluconeogenesis rather than oxidative entry into the tricarboxylic acid (TCA) cycle in vivo. Mechanistically, Pck1 gain- and loss-of-function experiments establish PCK1 as a non-redundant downstream effector of EZH2's pro-fibrotic action. Collectively, our findings uncover an EZH2-PCK1 epigenetic-metabolic axis that couples histone methylation to gluconeogenic reprogramming and fibrogenesis. This axis may offer a dual therapeutic opportunity for CKD by concurrently restoring metabolic homeostasis and limiting fibrotic progression.
中文摘要:慢性肾脏病(CKD)是全球致病和致死的重要原因。肾脏是主要糖异生器官,肾脏糖异生受损促进CKD,但调控机制仍不清楚。本研究发现组蛋白H3K27三甲基转移酶zeste同源增强子2(EZH2)以表观遗传方式抑制肾脏糖异生并驱动肾小管间质纤维化。通过整合多组学分析(RNA-seq、CUT&Tag和单核RNA-seq),我们发现EZH2直接结合近端小管细胞中糖异生基因启动子并沉积H3K27三甲基化,对磷酸烯醇式丙酮酸羧激酶(Pck1)基因的抑制作用最明显。在纤维化肾脏中,Ezh2在近端小管显著上调,并在损伤和适应不良修复状态下与Pck1表达呈负相关。遗传性敲除或药物抑制EZH2可恢复PCK1表达,增强乳酸向葡萄糖转化,并减轻培养小管细胞和小鼠肾纤维化模型中的细胞外基质沉积和纤维化标志物表达。稳定同位素13C-乳酸示踪显示,小管Ezh2缺失增加糖异生中间产物的标记分数,同时降低乙酰辅酶A的标记分数,表明体内乳酸来源碳优先分配至糖异生而非氧化进入三羧酸(TCA)循环。机制上,Pck1功能获得和缺失实验确立PCK1是EZH2促纤维化作用的非冗余下游效应分子。我们的发现揭示了一条EZH2-PCK1表观遗传-代谢轴,将组蛋白甲基化与糖异生重编程和纤维化生成联系起来。该轴可能通过同时恢复代谢稳态和限制纤维化进展,为CKD提供双重治疗机会。

4肾小球疾病 (1篇)

基础研究 (1篇)

Clinical reviews in allergy & immunology IF 11.5 2026-10-14 PMID: 42873393
Autoimmune diseases are characterized by loss of immune tolerance and substantial heterogeneity across patients, tissues, and disease stages. Although bulk transcriptomic studies have identified important inflammatory pathways, they cannot directly resolve rare, transitional, and tissue-contextualized cell states that may be relevant to disease mechanisms and therapeutic response. Single-cell RNA sequencing (scRNA-seq) enables transcriptomic profiling at cellular resolution, while complementary multimodal, receptor-repertoire, epigenomic, and spatial approaches can link cellular states to protein phenotype, clonal architecture, regulatory programs, and tissue context. This review critically examines recent single-cell studies in rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis, type 1 diabetes, and multiple sclerosis. Rather than providing a descriptive catalogue of published studies, we assess the strength of available evidence by distinguishing independently replicated findings from observations supported by limited studies, and cross-sectional associations from longitudinal, treatment-response, and functional evidence. Across the selected diseases, studies repeatedly report inflammatory programs involving interferon signaling, chemokine-mediated immune recruitment, and stromal-immune interactions; however, evidence for convergence at the cell-state and regulatory-network levels remains limited, and the extent to which shared signatures represent common pathogenic mechanisms rather than inflammatory context remains uncertain. We evaluate the translational potential of scRNA-seq for biomarker discovery, patient stratification, and treatment response prediction, while considering evidence from related tissue-based molecular stratification approaches, including the R4RA randomized trial in rheumatoid arthritis. R4RA provides prospective randomized evidence that synovial molecular features can enrich for differential therapeutic responses, but its use of bulk synovial transcriptomics and histopathology does not constitute prospective validation of single-cell-derived biomarkers. We further highlight cohort biases, reproducibility challenges, dissociation artifacts, computational ambiguity, and privacy concerns that constrain immediate clinical implementation. Together, these advances position single-cell profiling as a mechanistic discovery platform with substantial translational promise, contingent on standardization, validation across diverse cohorts, and integration with functional perturbation approaches.
中文摘要:自身免疫病的特征是免疫耐受丧失,以及患者、组织和疾病阶段之间存在显著异质性。批量转录组研究已识别重要炎症通路,但无法直接解析可能与疾病机制和治疗反应相关的稀有、过渡性和组织情境化细胞状态。单细胞RNA测序(scRNA-seq)可在细胞分辨率进行转录组分析,互补的多模态、受体库、表观基因组和空间方法可将细胞状态与蛋白表型、克隆结构、调控程序和组织背景联系起来。本综述批判性审视类风湿关节炎、系统性红斑狼疮及狼疮肾炎、1型糖尿病和多发性硬化中的近期单细胞研究。文章不以描述性目录罗列已发表研究,而是评估现有证据强度,区分可独立重复的发现与仅由有限研究支持的观察,区分横断面关联与纵向、治疗反应及功能证据。在所选定疾病中,研究反复报道涉及干扰素信号、趋化因子介导的免疫募集和基质-免疫相互作用的炎症程序;然而,细胞状态和调控网络层面的汇聚证据仍有限,共享特征在多大程度上代表共同致病机制而非炎症背景仍不确定。我们评估scRNA-seq在生物标志物发现、患者分层和治疗反应预测方面的转化潜力,同时考虑相关基于组织的分子分层方法的证据,包括类风湿关节炎中的R4RA随机试验。R4RA提供前瞻性随机证据,表明滑膜分子特征可富集不同治疗反应,但其使用批量滑膜转录组和组织病理学并不构成对单细胞来源生物标志物的前瞻性验证。我们进一步强调限制即时临床实施的队列偏倚、可重复性挑战、解离伪影、计算模糊性和隐私问题。这些进展共同将单细胞图谱定位为具有重大转化前景的机制发现平台,但其实现取决于标准化、多样队列验证以及与功能扰动方法的整合。

5糖尿病肾病 (1篇)

基础研究 (1篇)

Biosensors & bioelectronics IF 11.8 2026-10-12 PMID: 42863204
Herein, a novel electrochemiluminescence (ECL) biosensor was constructed based on a Nb2C/Nb2O5/ZnO QDs ternary heterojunction and heterogeneous interface interlocking (HII) hydrogel self-supporting electrode, which achieved sensitive and specific detection of miR-192-5p in extracellular vesicles (EVs) from diabetic nephropathy (DN)urine and serum samples. This Nb2C/Nb2O5/ZnO QDs heterojunction integrated the S-scheme heterojunction between Nb2O5 and ZnO QDs with the Schottky junction between Nb2C and Nb2O5. On the one hand, Nb2O5 acted as a bridging medium to drive directional migration of electrons and holes, which overcame the incomplete charge separation in traditional binary heterojunctions. On the other hand, Nb2C nanosheets provided directional electron transport channels and served as a coreactant reservoir, effectively promoting electron injection and exciting ZnO QDs to generate enhanced ECL signals at low voltage. Meanwhile the HII hydrogel electrode achieved dual electrical-ionic conductivity with excellent biocompatibility and stability, significantly boosting the ECL sensing performance. The Nb2C/Nb2O5/ZnO QDs heterojunction -HII hydrogel biosensor was used to detect miR-192-5p with a linear range of 1 fM-1 nM and a detection limit of 0.33 fM. Clinical detection results revealed miR-192-5p was upregulated in urinary EVs and downregulated in serum EVs of DN patients with disease progression. This biosensor enabled early, non-invasive and multidimensional DN diagnosis, providing a novel analytical strategy for precise DN detection and clinical application.
中文摘要:构建了一种基于Nb2C/Nb2O5/ZnO量子点三元异质结和异质界面互锁(HII)水凝胶自支撑电极的新型电化学发光(ECL)生物传感器,实现了对糖尿病肾病(DN)尿液和血清样本细胞外囊泡(EVs)中miR-192-5p的灵敏、特异检测。该Nb2C/Nb2O5/ZnO量子点异质结将Nb2O5与ZnO量子点之间的S型异质结和Nb2C与Nb2O5之间的肖特基结集成在一起。Nb2O5作为桥接介质驱动电子和空穴定向迁移,克服了传统二元异质结中电荷分离不充分的问题。Nb2C纳米片提供定向电子传输通道并作为共反应物储库,有效促进电子注入并激发ZnO量子点在低电压下产生增强的ECL信号。HII水凝胶电极兼具电子-离子双重导电性、良好的生物相容性和稳定性,显著提升了ECL传感性能。该Nb2C/Nb2O5/ZnO量子点异质结-HII水凝胶生物传感器用于检测miR-192-5p,线性范围为1 fM至1 nM,检出限为0.33 fM。临床检测结果显示,随着疾病进展,DN患者尿液EVs中miR-192-5p表达上调,血清EVs中表达下调。该生物传感器可用于DN的早期、无创和多维度诊断,为DN精准检测及临床应用提供了新的分析策略。